Ritonavir-boosted nirmatrelvir: Difference between revisions
m (Rossdonaldson1 moved page Paxlovid to Ritonavir-boosted nirmatrelvir) |
No edit summary |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[COVID]]=== | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 45: | Line 45: | ||
==Comments== | ==Comments== | ||
*Nirmatrelvir tablets and ritonavir tablets ('''Paxlovid''' from Pfizer) | |||
**treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) that are high risk | |||
**initiate within 5 days of symptom onset | |||
** 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days | |||
** renally dosed eGFR 30-60 then 150 mg/100 mg dosing | |||
**89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population. | |||
** Many [https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-paxlovid-drug-drug-interactions/ drug interactions] | |||
***E.g. Plavix, Phenytoin, Tacrolimus, Tramadol, Statins, Hydro/oxycodone/Codeine, Diazepam/Clonazepam/Alprazolam, Fentanyl, Tamsulosin | |||
** [https://lacounty.sharepoint.com/:x:/r/sites/dhs-Pharmacy/_layouts/15/doc2.aspx?sourcedoc=%7B6e13753f-6036-40ed-9f08-a566c6e215dd%7D&action=view&wdLOR=cEEBD2538-3432-4503-A554-5045C08AAE8A&activeCell=%27Inventory%27!C19&wdinitialsession=568aeaba-de75-4d27-856a-99f34a708416&wdrldsc=2&wdrldc=1&wdrldr=AccessTokenExpiredWarning%2CRefreshingExpiredAccessT DHS daily supply of COVID oral therapies] | |||
**[https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Antiviral-Therapeutics.aspx List of community pharmacies that might have COVID antivirals] | |||
***Printable list for patients [[File:COVID-19 Antiviral Providers.pdf|thumb|COVID-19 Antiviral Providers]] | |||
==See Also== | ==See Also== | ||
Revision as of 20:19, 18 January 2022
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names: Paxlovid
Adult Dosing
COVID
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- Nirmatrelvir tablets and ritonavir tablets (Paxlovid from Pfizer)
- treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) that are high risk
- initiate within 5 days of symptom onset
- 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days
- renally dosed eGFR 30-60 then 150 mg/100 mg dosing
- 89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population.
- Many drug interactions
- E.g. Plavix, Phenytoin, Tacrolimus, Tramadol, Statins, Hydro/oxycodone/Codeine, Diazepam/Clonazepam/Alprazolam, Fentanyl, Tamsulosin
- DHS daily supply of COVID oral therapies
- List of community pharmacies that might have COVID antivirals
- Printable list for patients File:COVID-19 Antiviral Providers.pdf